WO2023234891A3 - Novel acetylcholinesterase inhibitors - Google Patents

Novel acetylcholinesterase inhibitors Download PDF

Info

Publication number
WO2023234891A3
WO2023234891A3 PCT/TR2023/050100 TR2023050100W WO2023234891A3 WO 2023234891 A3 WO2023234891 A3 WO 2023234891A3 TR 2023050100 W TR2023050100 W TR 2023050100W WO 2023234891 A3 WO2023234891 A3 WO 2023234891A3
Authority
WO
WIPO (PCT)
Prior art keywords
acetylcholinesterase inhibitors
novel
novel acetylcholinesterase
inhibitors
methods
Prior art date
Application number
PCT/TR2023/050100
Other languages
French (fr)
Other versions
WO2023234891A2 (en
Inventor
Şeref DEMIRAYAK
Barkin BERK
Sevde Nur BILTEKIN KALELI
Zafer ŞAHIN
Original Assignee
Istanbul Medipol Universitesi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from TR2022/001550 external-priority patent/TR2022001550A2/en
Application filed by Istanbul Medipol Universitesi filed Critical Istanbul Medipol Universitesi
Publication of WO2023234891A2 publication Critical patent/WO2023234891A2/en
Publication of WO2023234891A3 publication Critical patent/WO2023234891A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to novel acetylcholinesterase inhibitors, methods of preparing acetylcholinesterase inhibitors according to the invention, and pharmaceutical compositions comprising the said acetylcholinesterase inhibitors.
PCT/TR2023/050100 2022-02-07 2023-02-07 Novel acetylcholinesterase inhibitors WO2023234891A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2022001550 2022-02-07
TR2022/001550 TR2022001550A2 (en) 2022-02-07 NEW ACETYLCHOLINESTERASE INHIBITORS

Publications (2)

Publication Number Publication Date
WO2023234891A2 WO2023234891A2 (en) 2023-12-07
WO2023234891A3 true WO2023234891A3 (en) 2024-04-04

Family

ID=89028294

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2023/050100 WO2023234891A2 (en) 2022-02-07 2023-02-07 Novel acetylcholinesterase inhibitors

Country Status (1)

Country Link
WO (1) WO2023234891A2 (en)

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ABEDINIFAR FAHIMEH; FARNIA S. MORTEZA F.; MAHDAVI MOHAMMAD; NADRI HAMID; MORADI ALIREZA; GHASEMI JAHAN B.; KüçüKK&#: "Synthesis and cholinesterase inhibitory activity of new 2-benzofuran carboxamide-benzylpyridinum salts", BIOORGANIC CHEMISTRY, ACADEMIC PRESS INC., NEW YORK, NY., US, vol. 80, 6 June 2018 (2018-06-06), US , pages 180 - 188, XP085445906, ISSN: 0045-2068, DOI: 10.1016/j.bioorg.2018.06.006 *
KULDEEP SINGH: "PIPERAZINE -A BIOLOGICALLY ACTIVE SCAFFOLD", INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH, SOCIETY OF PHARMACEUTICAL SCIENCES AND RESEARCH, PNACHKULA (HR), IN, vol. 6, no. 11, 1 November 2015 (2015-11-01), IN , XP093158341, ISSN: 2320-5148, DOI: 10.13040/IJPSR.0975-8232.6(10).4145-58 *
YULU MA: "Design, Synthesis, and Biological Evaluation of Novel Benzofuran Derivatives Bearing N-Aryl Piperazine Moiety", MOLECULES, MDPI AG, CH, vol. 21, no. 12, CH , pages 1684, XP093158340, ISSN: 1420-3049, DOI: 10.3390/molecules21121684 *

Also Published As

Publication number Publication date
WO2023234891A2 (en) 2023-12-07

Similar Documents

Publication Publication Date Title
MX2022015272A (en) Inhibitors of kras g12c protein and uses thereof.
MX2023008031A (en) Gcn2 inhibitors and uses thereof.
MX2022014007A (en) Compounds as bcl-2 inhibitors.
AU2020281332A8 (en) Dna-dependent protein kinase inhibitor
MX2023003264A (en) Cdk inhibitors and their use as pharmaceuticals.
WO2021257730A3 (en) Cells modified by a cas12i polypeptide
MX2023007265A (en) Cdk inhibitors and their use as pharmaceuticals.
WO2021158635A8 (en) Anti-viral compositions and methods of use
MX2023004869A (en) Antibodies against sars-cov-2 and uses thereof.
MX2022001449A (en) Human aminosterol ent-03 compounds, related compositions comprising the same, and methods of using the same.
GB0216002D0 (en) Process and composition
WO2022132596A3 (en) Tissue-specific antigens for cancer immunotherapy
WO2021100029A3 (en) Prodrugs of fulvestrant
EA202091280A1 (en) METHOD FOR OBTAINING FOOD PRODUCTS CONTAINING RYE
MX2022001641A (en) Fermented compositions and processes of preparing the same.
WO2020146700A8 (en) Lipid nanoparticles
MX2023001504A (en) Compounds as c5ar inhibitors.
MX2023002117A (en) Amorphous form of a malt1 inhibitor and formulations thereof.
WO2023234891A3 (en) Novel acetylcholinesterase inhibitors
WO2022040111A3 (en) Solid state forms of erdafitinib salts and processes for preparation of erdafitinib
WO2020139971A3 (en) Methods for making dimeric naphthalimides and solid state forms of the same
WO2022169961A8 (en) Sigma receptor ligands for treating sars-cov-2 infection
ZA202207539B (en) Composition and methods of manufacture
WO2022118016A3 (en) Enzyme inhibitors
MX2023000198A (en) Atr inhibitors and uses thereof.